Background Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis. Solid tumors pose many barriers to immunotherapies, including therapy half-life and persistence, tumor penetrance, and targeting. Therapeutics delivered systemically may not traffic to the tumor site. If cellular therapies or drugs are able to access the tumor site, or can be delivered directly within the tumor, treatments may not persist for the duration necessary to reduce or eliminate tumor burden. An approach that allows durable and titratable local therapeutic protein delivery could improve antitumor efficacy while minimizing toxicities or unwanted on-target, off-tissue effects.
Methods In this study, human monocyte-derived macrophages were genetically engineered to secrete a bispecific T cell engager (BiTE) specific to the mutated epidermal growth factor variant III (EGFRvIII) expressed by some GBM tumors. We investigated the ability of lentivirally modified macrophages to secrete a functional BiTE that can bind target tumor antigen and activate T cells. Secreted BiTE protein was assayed in a range of T cell functional assays in vitro and in subcutaneous and intracranial GBM xenograft models. Finally, we tested genetically engineered macrophages (GEMs) secreting BiTE and the proinflammatory cytokine interleukin (IL)-12 to amplify T cell responses in vitro and in vivo.
Results Transduced human macrophages secreted a lentivirally encoded functional EGFRvIII-targeted BiTE protein capable of inducing T cell activation, proliferation, degranulation, and killing of antigen-specific tumor cells. Furthermore, BiTE secreting macrophages reduced early tumor burden in both subcutaneous and intracranial mouse models of GBM, a response which was enhanced using macrophages that were dual transduced to secrete both the BiTE protein and single chain IL-12, preventing tumor growth in an aggressive GBM model.
Conclusions The ability of macrophages to infiltrate and persist in solid tumor tissue could overcome many of the obstacles associated with systemic delivery of immunotherapies. We have found that human GEMs can locally and constitutively express one or more therapeutic proteins, which may help recruit T cells and transform the immunosuppressive tumor microenvironment to better support antitumor immunity.
- cell engineering
- tumor microenvironment
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Although recent advancements in cancer immunotherapy have shown rapid progress in the elimination of blood cancers, the treatment of solid tumors has progressed much more slowly. This is especially true of glioblastoma (GBM), where therapies such as checkpoint inhibitors and chimeric antigen receptor (CAR) T cells have not significantly extended patient survival.1 2 Major obstacles to successful immunotherapy for GBM include the restricted recruitment of T cells to the brain, the immunosuppressive tumor microenvironment (TME), and the low mutagenic burden of most GBM tumors.3
Bispecific T cell engagers (BiTEs) are a class of immunotherapeutic proteins designed to facilitate the interactions of T cells and tumor cells via binding of a tumor-specific antigen on one single chain variable fragment (scFv), and the CD3ε receptor on T cells, with the goal of inducing a polyclonal T cell response to a tumor antigen. Dual engagement of the BiTE with the T cell and target cell induces T cell activation and release of lytic granules that result in target cell killing. Therefore, BiTEs, much like CAR T cells, offer a method to activate polyclonal T cell populations in a non-Major Histocompatibilty Complex (MHC)-restricted manner to kill cancer cells. In contrast to CAR T cells, BiTEs are relatively small, and therefore better able to penetrate solid tumors, where they could engage T cells. BiTE stimulation not only induces killing of tumor cells4 but can also reverse the immunosuppressive functions of regulatory T cells often described in GBM tumors.5
Indication-specific BiTEs are approved for the treatment of leukemia and are in clinical trials for the treatment of many types of solid tumors.6 A BiTE targeted to the mutated epidermal growth factor variant III (EGFRvIII), which is expressed by tumor cells in 30% of GBM patient tumors, has shown significant promise in preclinical models,7 and is currently being tested in patients.8 However, BiTEs also have disadvantages, such as suboptimal tissue penetrance, lack of tumor targeted delivery, and short half-lives.9 These disadvantages require frequent high-dose systemic administration to achieve efficacy, which can be associated with off-target toxicities.10 Reducing treatment frequency and toxicities through sustained local delivery may therefore be of benefit to improving outcomes and quality of life for patients treated with BiTEs.
We have previously reported an engineered macrophage cellular therapy that capitalizes on the natural penetrance and accumulation of macrophages in the GBM TME.11 Tumor tissue penetrance and long-term persistence of engineered macrophages in vivo suggest that this platform could alter the TME, allowing recruitment and activation of antitumor immune cells. In this study, we engineered human monocyte-derived macrophages to secrete a BiTE specific to the tumor antigen EGFRvIII, and evaluated the ability of secreted BiTE to trigger T cell activation and killing of tumor cells in vitro and in vivo. BiTE-secreting genetically engineered macrophages (GEMs) induced T cell activation and tumor cell killing in an EGFRvIII-dependent fashion. In vivo, EGFRvIII BiTE GEMs suppressed early tumor growth. Dual-transduced GEMs secreting EGFRvIII BiTE and interleukin (IL)-12 similarly activated T cell killing of tumor targets, and were sufficient to prevent tumor GBM growth in vivo. Collectively, our data suggest that GEMs may be used as a stand-alone treatment or as an adjuvant to other immunotherapy approaches.12–16
Materials and methods
EGFRvIII lentivirus was used to generate EGFRvIII-expressing U87 cell lines. BiTE, truncated CD19 negative control (CD19t), mCherry, and IL-12 sequences were synthesized by GeneArt (Carlsbad, California, USA) and inserted in epHIV7.2 (11) backbone between NheI and Not1 restriction enzyme sites. This plasmid was transfected into 293T cells along with modified packaging plasmids and a plasmid encoding the Vpx protein as described.11 Virions were collected from transfected 293T cell supernatants and concentrated by ultracentrifugation (90 min, 24.5 K rpm, 4°C). Viral titer was determined using the QuickTiter Lentivirus Titer kit (Cell Biolabs).
293T (ATCC-CRL-1326) and U87 (ATCC-HTB14) cell lines were obtained from ATCC. EGFRvIII eGFP-ffluc Raji and EGFRvIII K562s were a gift from the Jensen lab. EGFRvIII overexpressing U87s were generated by transduction of 1.0×106 U87s with EGFRvIII-epHIV7.2 and eGFP-ffluc-epHIV7.2 at an multiplicity of infection (MOI) of 1 with 0.025 mg/mL protamine sulfate (Fresenius Kabi).
Human monocyte-derived macrophages were generated by CD14 isolation from healthy plasma donor peripheral blood products (BloodWorks NW) using a previously described protocol.11 Briefly, CD14+ cells were isolated using an Easy Sep Human CD14 positive selection kit (Stem Cell Technologies) and differentiated with 10 ng/mL human granulocyte-macrophage stimulating factor (GMCSF) (R&D Systems) in Roswell Park Memorial Institute (RPMI) (Gibco)/10% fetal bovine serum (FBS) (Peak Serum). Three days later, 100% of cytokine and 50% media were refreshed. On day 6, cells were trypsinized, counted, and replated (60 000 cells/cm2).
T cells were isolated from macrophage donor-matched peripheral blood mononuclear cells (PBMCs) using the Human CD3 Positive Selection Kit II (Stem Cell Technologies). Cells were plated at stated densities with 30 U/mL recombinant human IL-2 (rhIL-2) where indicated (R&D Systems). T cells were stimulated with Dynabeads (Gibco) according to manufacturer’s instructions.
Antibodies and cell stains
Flow cytometry antibodies
Biolegend: CD19-PE (clone HIB19), CD4-Alexa647 (clone OKT4), CD4-BV510 (clone peripheral), CD3-BV605 (clone OKT3), CD69-PE (clone FN50), CD69-FITC (clone FN50), CD107a-BV421 (clone H4A3), PD-1-PECy7 (clone EN12.2H7), IFNγ-BV785 (clone 4S.B3), TNFα-Alexa647 (clone Mab-11), CD40L-PEDazzle594 (clone 24–31),
Becton Dickinson: CD3-FITC (clone UCHT-1), CD8-PerCPCy5.5 (clone RPA-T8), CD25-APC-H7 (clone M-A251), Granzyme B-A700 (clone GB11), Fc block (Clone: 3070), Fixable Viability Stain 520 (BD Horizon), Live/Dead UV450/50 (Invitrogen), Cell Trace Violet (Invitrogen), His-PE (Miltenyi, clone GG11-8F3.5.1), anti-6X His tag antibody [HIS.H8] (AbCAM, Cat. No. ab18184), IRDye 800CW Goat anti-mouse IgG secondary antibody (Li-COR Biosciences, Cat. No. 926–32210).
Woodchuck hepatitis virus post-transcriptional response element (WPRE) assay
Transduced macrophage (day 7 post-transduction) genomic DNA was isolated, according to the manufacturer’s recommended protocol (Qiagen), concentrated to 50 ng/µL, and quantitative PCR (qPCR) was performed. Further, 10-point standard curves were generated using epHIV7 (1 WPRE construct/molecule) and pCMV6-AC (1 albumin construct/molecule). Copy number/cell was determined by normalizing WPRE starting quantity (sq) to albumin sq using the following equation: (WPRE sq/albumin sq×2).
CD19 truncated marker staining
Macrophages transduced with 125–750 LP/cell BiTE-encoding lentivirus, dual transduced with BiTE (750 LP/cell) and IL-12 (250 LP/cell) lentiviruses, or untransduced were harvested on day seven post-transduction with TrypLE Express. Macrophages were incubated with human Fc block (50 µg/mL), stained with a live/dead dye and anti-CD19 antibody, fixed with 2% paraformaldehyde, and analyzed by flow cytometry.
293T supernatant was collected 4 days post-transfection and then purified according to recommended protocol with protein L magnetic beads (Pierce) or a nickel column generated from Nickel (Ni) Sepharose 6 Fast Flow beads in HisTrap FF columns (GE Healthcare). Purified proteins were run on an Sodium Dodecyl Sulfate Polyacrilamide Gel Electrophoresis (SDS-PAGE) gel and then transferred to a Millipore membrane. Following transfer, the membrane was blocked with Odyssey blocking buffer (LI-COR) and probed with anti-His antibody (Abcam HIS-H8, ab18184, 1:1000), followed by an anti-mouse secondary antibody (Li-COR, 926–32 210, 1:10 000). The membrane was imaged and analyzed on an Odyssey CLx Infrared Imaging System.
293T cells were transfected with 2.5 µg plasmid DNA encoding the BiTE lentivirus with GMCSF and H7 secretion sequences according to the Mirus Bio TransIT-LT1 Transfection protocol and supernatant was collected 3 days later. BiTE-transduced macrophage supernatant was collected from 3×106 transduced macrophages plated in 10 cm dish (days 7–14). Supernatant was concentrated using a 10 mL spin column (4000×g for 20 min) and purified using Ni Sepharose 6 Fast Flow (GE Healthcare) beads followed by protein L magnetic beads (Pierce). Then, 50 µL was added to the His ELISA according to manufacturer’s protocol.
EGFRvIII binding assay
Unconcentrated supernatant from transfected 293T (day 3) or transduced macrophages (day 7) was added to 1.0×106 EGFRvIII-overexpressing K562 cells for 20 min. Cells were subsequently stained with anti-His PE antibody (Miltenyi, clone GG11-8F3.5.1) and analyzed using flow cytometry.
Gene expression analysis
5.0×105 GMCSF-differentiated macrophages were transduced and cultured with 2.0×105 EGFRvIII-expressing U87s and 3.0×106 T cells isolated from autologous PBMCs. Three days later, T cells in suspension were collected and RNA prepared using the RNeasy Mini Kit (Qiagen). Further, 25 ng of RNA was analyzed using the human immunology v2 panel (NanoString). Threshold values were defined as two times the average background of negative controls, and gene expression was normalized to internal housekeeping genes. Secreted proteins were quantified using the Bio-Plex Pro Human Immunotherapy Panel, 20 plex (BioRad) and analyzed using the Bio-Plex Manager Software.
T cell coculture assays
Supernatant from 5.0×105 transduced macrophages or 2 mL transfected 293T cells were cultured with T cells and EGFRvIII-K562 or U87 target cells (3–4 days). Cells were stained for CD3, CD4, CD8, CD25, CD69, and PD-1 and Live/Dead. For degranulation assays, T cells were added to transduced macrophages (day 6 post-transduction) for 2 days prior to the addition of target cells, FcR blocking antibody, and CD107a antibody for 6 hours. For proliferation assays, T cells were labeled using the CellTrace Cell Proliferation Kit (Invitrogen) and incubated for 6 days, with introduction of 2.0×105 new targets on day 3. For intracellular staining, brefeldin A was added 5 hours prior to harvesting cells and staining. All samples were run on a BD LSR Fortessa flow cytometer using FACS DIVA software and analyzed with FlowJo V.10.
GEMs were incubated on day 7 post-transduction with 500 µL resuspended pHrodo RED particles (Invitrogen) for 90 min at 37°C. Following incubation, macrophages were lifted with TrypLE and analyzed via flow cytometry.
Macrophages were transduced with mCherry lentivirus at 500 LP/cell in combination with CD19t (750 LP/cell), BiTE (750 LP/cell), or BiTE (750 LP/cell) and IL-12 (250 LP/cell) lentivirus. Six days post-transduction, GEMs were replated at 62 500 cells/well. The following day, 20 833 EGFRvIII eGFP-ffluc Raji target cells were added and the plate was live imaged every 10 min for 24 hours using the Incucyte live cell imager (Essen Biosciences, Ann Arbor, Michigan, USA). Green Fluorescent Protein (GFP) counts were determined over time.
Chromium (Cr-51) release assay
GMCSF-differentiated macrophages were plated at 1.5×104/well. Twenty-four hours later, macrophages were transduced with 750 LP/cell BiTE lentivirus with or without IL-12 lentivirus (250 LP/cell), IL-12 alone (250 LP/cell) or CD19t control lentivirus (750 LP/cell). Autologous PBMCs were used for CD3 isolation or plated overnight in IL-2 before addition of PBMCs or T cells to macrophages or 1 ng control purified BiTE protein, followed by addition of 5.0×103 Cr51-labeled EGFRvIII-U87 target cells for 18 hours. Supernatants were harvested onto a filter, read on a TopCount, and percent lysis determined.
Supernatant from 5.0×105 BiTE/IL-12 or IL-12-transduced macrophages was collected 7 days after transduction and analyzed using the IL-12 Bioplex protocol (BioRad).
Immunohistochemistry of mouse tumor samples
Formalin-fixed paraffin-embedded tumor sections were deparaffinized and pretreated with DIVA decloaking buffer (Biocare medical) at 125°C. Sections were blocked for 1 hour in 0.2% Bovine Serum Albumin (BSA)+2% normal goat serum (Jackson Immuno). Sections were stained with rat anti-human CD3 (BioRad, clone CD3-12, #MCA1477) at 1:100 and rabbit anti-human CD8 (Abcam, polyclonal,#ab4055) diluted 1:100 in blocking buffer for 1 hour, 25°C. Sections were stained with goat anti-rat AlexaFluor 488 (Thermo, #A11006) and goat anti-rabbit AlexaFluor 568 (Thermo, #A11011) each diluted 1:500 in blocking buffer for 1 hour, 25°C. Sections were then stained for 10 min in Hoechst dye (Thermo, #H3570) at 2 μg/mL in ddH2O, and coverslipped with Prolong Gold (Thermo #P36935). Sections were imaged at ×40 (Plan apo, NA 0.95) on a Nuance Multispectral camera (Akoya Biosciences) with a Nikon Eclipse Ci microscope and images were analyzed with InForm Tissue Analysis software, V.2.4 (Akoya Biosciences).
In vivo subcutaneous models
1.0×106 eGFP-ffluc EGFRvIII U87s cells in a 50/50% matrigel/cells in 100 µL Phosphate Buffered Saline (PBS) were injected subcutaneously into the right flank of NSG mice (Jackson Laboratory). Eighteen days later, 1.0×106 GEMs were injected intratumorally, followed by intravenous injection of 1.0×107 Dynabead activated T cells. Positive control animals received five daily intratumoral injections of 1 µg purified BiTE protein and 12 ng rhIL-12 starting on day 18. For the BiTE and IL-12 GEM combination study, 1.0×106 eGFP-ffluc EGFRvIII U87s and 5×105 GEMs with or without 2.5×105 IL-12 GEMs were injected subcutaneously into the right flank of NSG mice. Seven days later, mice received an intravenous injection of 1×107 Dynabead activated T cells that had been rested 5 days in 30 U/mL recombinant human IL-2. A single injection of intratumoral human purified BiTE protein (10 ng) or BiTE protein in combination with recombinant human IL-12 (12 ng) on the day of T cell injection was given as a control. Tumor growth was measured using bioluminescence and tumor volume twice weekly. For luminescence measurements, mice were anesthetized with isoflurane and injected subcutaneous with D-luciferin. Fifteen minutes post-luciferin injection, mice were imaged on an Xenogen IVIS In Vivo Imaging System. Tumor volume was calculated using the following formula: volume=(width2×length/2). Mice were euthanized when tumor size reached 2000 mm3.
In vivo intracranial model
Intracranial injection of eGFP-ffluc EGFRvIII U87s was performed as previously described.17 Briefly, 2.0×105 eGFP-ffluc EGFRvIII U87s in 2 µL of PBS were injected intracranially (2 mm lateral, 0.5 anterior to bregma and 2.5 mm deep from dura). Six days later, 3.0×105/6 µL GEMs were injected into the tumor. 3.0×105 T cells were injected intratumorally 3 days later, and tumor burden was measured by bioluminescence three times weekly.
In approximately 30% of patients with GBM, tumor cells express a mutated form of EGFR with a constitutively active tyrosine kinase, known as EGFRvIII.8 We created a macrophage-specific lentiviral vector encoding a BiTE that binds EGFRvIII (806 single scFv) and the T cell-engaging anti-CD3 OKT3 scFv, and modified the design to enhance production using short linker as described6 and added a histidine (His) tag (online supplemental figure 1A). To validate the EGFRvIII BiTE construct function, supernatant was harvested from transfected 293T cells and cultured with T cells. 293T BiTE supernatant increased expression of the activation markers CD25 (online supplemental figure 1B) and CD69 (online supplemental figure 1C) on CD4 and CD8 T cells cultured with EGFRvIII-expressing K562 target cells. Supernatants from transfected 293T cells and GEMs were purified using a nickel column (Ni+) or magnetic protein L beads (L+) after which BiTE protein was detected using an anti-His antibody (online supplemental figure 1D), validating that the BiTE construct encodes a functional secreted protein.
BiTE GEMs were generated by transducing human monocyte-derived macrophages with BiTE-encoding epHIV7.2 lentivirus.11 As macrophages do not express endogenous CD19, a truncated, non-signaling CD19 (CD19t)18 was encoded downstream of the BiTE sequence to measure transduction efficiency (online supplemental figure 1A). Flow cytometry showed that CD19t positive macrophages increased with escalating doses of lentivirus (figure 1A). Consistent with this observation, analysis of viral integration events, performed by quantifying WPRE copy numbers, increased with lentiviral concentrations (n=3 donors, figure 1B). Based on these data, macrophages were transduced using 750 lentiviral particles (LPs) per cell for subsequent experiments (figure 1A, online supplemental figure 2A).
To ensure that no post-translational events prevent BiTE secretion by GEMs, we tested supernatant after transduction relative to the negative control macrophages transduced with lentivirus encoding only CD19t (CD19t GEMs). Although we did not detect BiTE protein by western blot (online supplemental figure 1D), it was detectable in BiTE GEM supernatant relative to CD19t GEMs using a competitive binding ELISA over 7 days (online supplemental figure 2B). Concentrated GEM supernatants were tested for BiTE secretion, contained an average of 63.4 ng/mL (figure 1C), a 16.4-fold increase over control CD19t GEMs. To determine if there was a correlation between integration events and BiTE protein concentration, we ran a WPRE assay and a sample-matched ELISA (n=9 donors). When transduced at 750 LPs/cell, there was a range of integration frequency from 150 to almost 500 copies/cell, which did not predict the secreted BiTE protein concentration (online supplemental figure 2C).
To test if lentivirally encoded BiTE secreted by macrophages bound the intended EGFRvIII tumor antigen, we cultured BiTE GEM supernatants with EGFRvIII-overexpressing K562 cells and stained cells using a fluorescently conjugated anti-His antibody (figure 1D). Relative to control GEM supernatants, a significant percentage of target cells bound the His-tagged BiTE protein (figure 1E, 19.35% vs 3.49%, p=0.036), indicating antigen-specific binding.
To optimize engineered BiTE secretion by GEMs, we compared a granulocyte-macrophage stimulating factor (GMCSF) secretion sequence and the antibody-specific heavy chain signal peptide 7 (H7) sequence, which is derived from the human immunoglobulin heavy chain sequence, and enhances antibody secretion in Chinese Hamster Ovary (CHO) cells.19 Although there was not a significant difference in BiTE protein secreted by transfected 293T cells (online supplemental figure 3A), the H7 secretion sequence BiTE GEMs induced consistently greater T cell activation than GEMs with the GMCSF secretion sequence BiTE (online supplemental figure 3B,C). The H7 secretion sequence was therefore incorporated into the lentiviral vector for subsequent experiments.
One advantage of using macrophages for protein delivery is their potential to provide essential costimulatory signals to tumor-infiltrating T cells. Following confirmation of EGFRvIII binding by the GEM-secreted BiTE, we tested the effects of GEMs on T cell activation. BiTE GEMs significantly increased expression of the activation markers CD25 (figure 2A) and CD69 (figure 2B) on the surfaces of CD4 (CD25, p<0.0001, CD69, p=0.0086) and CD8 (CD25, p=0.0233, CD69, p=0.0019) T cells in the presence of antigen-expressing GBM tumor cell targets (U87+) relative to control CD19t GEMs. T cells also significantly increased the expression of CD40L (AVG CD4/CD8) (figure 2C, CD4 p=0.0475, CD8 p=0.0067), interferon γ (IFNγ) (figure 2D, CD4 p=0.0001, CD8 p=0.0001), and tumor necrosis factor α (TNFα) (figure 2E, CD4 p=0.0002, CD8 p=0.0003). Within 5 hours, increases in T cell cytokine production were measurable relative to controls (online supplemental figure 4A,B). Consistent with prolonged activation, T cells increased programmed death-1 (PD-1) in coculture (online supplemental figure 4C).
To compare the effects of BiTE GEMs relative to BiTE protein alone, we tested gene expression in T cells incubated with EGFRvIII-U87 target cells and either BiTE GEMs or equivalent concentrations of purified BiTE protein. BiTE GEMs increased genes associated with T cell activation and IFNγ signaling (SLAMF7, IL2RA, BATF3, IRF4), T cell recruitment (CCL18, CXCL9, CXCL13), and killing (GZMB, LAMP3) relative to T cells incubated with purified BiTE protein (figure 2F). Gene ontogeny analysis indicated that the 50 genes with the greatest increase in expression were involved in cell responses to stimuli, cell communication, and signaling (online supplemental figure 4D).
Consistent with increased cytokine production detected by flow (figure 2D and E), exposure to BiTE GEMs significantly increased secreted TNFα (p=0.0059) and IFNγ (p=0.0052) in coculture supernatants (figure 3A). BiTE GEMs also induced cytokines necessary for T cell survival (figure 3B), such as IL-2, IL-7, and IL-15, and those associated with different helper T cell subsets (figure 3C). In addition to T cell-specific proinflammatory cytokines, interferon-inducible chemokine (IP-10, p=0.0018) and cytokines associated with an inflammatory immune response, IL-8 (p=0.0032) and IL-18 (p=0.0049) were also significantly increased (figure 3D). GEMs cocultured with autologous T cells also retained their ability to phagocytose both beads using flow cytometry (figure 3E, left) and tumor cells using longitudinal Incucyte imaging (figure 3E, right), which was independent of lentiviral transduction, suggesting that GEMs may both contribute to tumor cell clearance and present tumor antigens to T cells following phagocytosis.20 21
Analysis of T cell gene expression (n=3 donors, performed in triplicate) showed that during coculture, BiTE GEMs induced genes important for T cell survival (IL2RA and IL2RB), memory development (PRDM1), cytokine signaling (CISH, IFNG, TNFAIP3, TNFRSF4, TNFRS9, IRF4, and IRF1), CTL response (GZMB and LAMP3), costimulatory molecules (ICOS and CD40), and antigen exposure (CTLA4, SLAMF, LTA, and LAG3) (figure 3F). TGFB1, which promotes tumor growth and suppresses antitumor immunity in glioma, was one of the most downregulated genes (figure 3F).22 This gene signature was associated with increased antigen-specific proliferation of CD4 and CD8 T cells (figure 3G), indicating the potential for BiTE GEMs to amplify proinflammatory immune responses by expanding antitumor T cells.
To measure the impact of BiTE GEMs on T cell cytotoxicity, we tested T cell CD107a and Granzyme B degranulation as well as target lysis. CD4 and CD8 T cells increased CD107a (figure 4A, CD4 p=0.0039, CD8 p=0.0026) and Granzyme B (figure 4B) degranulation in the presence of EGFRvIII tumor targets. Both CD4 T cells (figure 4B, top) and CD8 (figure 4B, bottom) were over 90% Granzyme B positive when incubated with autologous BiTE GEMs in the presence of EGFRvIII-U87s, representing a 55.25-fold increase for CD4 T cells (p=0.003) and a 2.19-fold increase for CD8 T cells (p=0.0768) relative to control cells. Chromium release assays showed that in comparison to CD19t control GEMs, BiTE GEMs induced significantly more autologous T cell (figure 4C, p=0.005), and PBMC lysis (figure 4E, p=0.009) of EGFRvIII-expressing U87 (U87+) cells. The highest concentration of T cell in the culture (25 T cells:3 GEM:1 U87 target), achieved equivalent lysis of target cells as the positive control purified BiTE protein (figure 4D), without the need to increase the number of GEMs in the coculture (figure 4C and E n=3 donors, performed in triplicate). Neither GEMs themselves, nor the immunosuppressive factors secreted by U87 cells, such as TGFβ, impaired antigen-specific killing.
We tested human BiTE GEMs in a subcutaneous (figure 5A–C, online supplemental figure 5A) xenograft mouse model by injecting BiTE GEMs into established EGFRvIII and luciferase-expressing U87 tumors, followed by intravenous injection of purified T cells, and measuring longitudinal bioluminescence. BiTE GEMs delayed tumor growth in early stages when compared with CD19t control GEMs (figure 5C, p=0.0815). This trend was consistent, but not as durable, when T cells were locally injected into an established intracranial model (figure 5D–F, online supplemental figure 5B,C), although the presence of GEMs secreting BiTE delayed tumor growth relative to mice injected with T cells only (online supplemental figure 5C). In both models, tumors rebounded at later time points, resulting in no significant extension of survival in either system (online supplemental figure 5A,B). In the subcutaneous tumor model, 20% of the mice from the BiTE GEM group survived longer than mice in the CD19t control GEM treatment group (online supplemental figure 5A). Histological analysis of tumor sections showed enhanced recruitment of CD3+ CD8+ and CD3+ CD8- T cells to the tumor following BiTE GEM injection, but not CD19t GEM injection (figure 5G). These findings are consistent with previous works showing that BiTE as a monotherapy has only modest efficacy in mouse tumor models.13 23
Because IL-12 is a well-known modulator of the TME,24 enhancing T and natural killer (NK) cell cytotoxicity, T cell differentiation to T helper 1 cells, and IFNγ production, we tested a combination of BiTE GEMs and macrophages engineered to produce IL-12 in vitro. Macrophages were transduced with two separate lentiviral constructs that encoded single chain bioactive IL-1225 and EGFRvIII BiTE (IL-12/BiTE GEMs). Both constructs include the CD19t sequence as marker of transduction. Dual transduced cells were 81.4% CD19 positive in comparison to the singly transduced BiTE cells (78.2% positive), a slight increase that was consistent in four donors (online supplemental figure 6A). Supernatant from dual transduced cells was also tested in comparison to supernatant from BiTE GEMs in the EGFRvIII binding assay as described in figure 1D. Dual transduction modestly decreased secreted BiTE protein binding to target cells (23% vs 30.9%) (online supplemental figure 6B), as well as the concentration of IL-12 in the supernatant (online supplemental figure 6C). BiTE secretion had the greatest impact on genes involved in T cell activation, with few genes modulated in T cells after culture with GEMs secreting only IL-12 relative to CD19t expressing GEMs (figure 6A). The presence of macrophages and the process of transduction, independent of lentiviral vector also supported T cell activation (online supplemental figure 6D,E), indicating the proinflammatory state of ex vivo differentiated and transduced GEMs. Gene ontogeny analysis shows that the genes activated in this setting are consistent with those observed after transduction with BiTE alone (online supplemental figure 6F).
In the flank U87 model, we found that the negative control, in which only T cells were injected, showed no delay in tumor growth, whereas the positive control testing T cells injected followed by intratumoral injection of purified BiTE protein and rhIL-12 resulted in complete resolution of subcutaneous tumor, indicating the potency of the combination (online supplemental figure 7A,B). To test effects on T cell functions in vitro, we performed gene expression analysis of T cells cultured with EGFRvIII target cells and either autologous BiTE GEMs or IL-12/BITE GEMs. We found that dual transduced GEMs increased IFNG in comparison to BiTE GEMs alone (figure 6A), as well as a number of proinflammatory surface and secreted proteins (online supplemental figure 7C). Increased IFNγ was not detected at the protein level in all donors (online supplemental figure 7C), possibly due to rapid internalization by T cells and GEMs in the culture. Dual transduced cells significantly increased amounts of the proinflammatory proteins GMCSF and RANTES, and cytokines IL-6 and IL-8 (online supplemental figure 7C), which recruit and retain effector T cells to sites of inflammation. Consistent with T cell activation and proliferation shown using unbiased pathway analysis (online supplemental figure 6F), IL2RA was increased in all donors (n=4, figure 6A) at the gene expression level, and IL-7 and IL-15 proteins were increased in supernatant (online supplemental figure 7C). IL-12 secretion also increased Granzyme B gene (figure 6A) and intracellular protein expression in CD4 T cells (figure 6B), although EGFRvIII targeted tumor cell cytotoxicity was dependent on GEM secretion of BiTE and was not significantly enhanced by the secretion of IL-12 (figure 6C).
To test the efficacy of BiTE/IL-12 produced by GEMs in vivo, GEMs were transduced with CD19t, BiTE alone, or both BiTE and IL-12, and injected into the flank U87 NSG tumor model (figure 6D). Intravenously injected T cells effectively prevented tumor growth for 36 days without any evidence of tumor (figure 6E–G), which was dependent on the transduction of GEMs with BiTE lentivirus, and enhanced with the dual production of BiTE and IL-12 (figure 6F). Intratumoral injection of purified BiTE or BiTE and IL-12 proteins delayed, but did not prevent tumor growth (figure 6G and H). Collectively, our data suggest that the GEM platform may have added therapeutic benefit when used to deliver one or more therapeutic proteins locally.
In the current study, human macrophages were engineered to secrete a functional BiTE. BiTE secreted by GEMs activated T cells, induced cytokines and antigen-specific target cell lysis. With the novel demonstration of GEM lentivirally encoded scFv secretion, this platform may be used to produce therapeutic scFvs that may have targeting or toxicity barriers in a variety of indications.
GEMs as a therapeutic platform offer other advantages over current cellular therapies. Not unlike dendritic cells, macrophages express several proteins important for antigen presentation, and support of T cell effector functions.26 27 This is supported here by the observation that GEMs induced more robust expression of activation genes and proteins than purified BiTE protein alone (figure 2). GEMs can also secrete a variety of therapeutic proteins, such as chemokines and cytokines, that could support proinflammatory immune responses in the TME. In contrast to CAR T or NK cells, macrophages do not proliferate,28 thereby preventing delivery of potentially toxic concentrations of lentivirally encoded therapeutic proteins caused by rapid and unregulated proliferation of adoptively transferred cells. A particular strength of macrophages as a therapeutic cell for solid tumors includes their propensity for trafficking to and accumulation in solid tumors.29–31 Our previous work demonstrates the long-term survival, persistence of lentivirally encoded gene expression, and dissemination of locally injected GEMs throughout tumor tissue in vivo.11 In the current study, our data extend on initial characterization to show the potential for therapeutic efficacy when locally administered. Although this is an appealing avenue for tumors that are easily accessible for local delivery, an approach currently in clinical trials for other therapeutic platforms,32 future studies will determine trafficking, recruitment, and efficacy of systemically injected GEMs for tumors that may be impossible to access, diffuse, multifocal, or metastatic.
The recent description of a macrophage engineered to express a human epidermal growth factor receptor 2-specific CAR capitalizes on the ability of macrophages to perform tumor-specific phagocytosis of tumor cells and expand the repertoire of peptides presented to T cells.20 21 Our data indicate that GEMs could contribute to this interaction by both clearing debris resulting from tumor cell lysis and cross presenting novel tumor antigens to T cells (figure 3E).
GEMs can be transduced with at least two different lentiviruses (figure 6), so this platform allows testing of several therapeutic protein combinations. In addition to IL-12, which can increase the visibility of the tumor to the immune system,33 34 costimulatory molecules or checkpoint inhibitors are also of interest. Although BiTE proteins do not require costimulation for T cell function,35 the addition of CD28 improves efficacy in mice.36–38 Increased PD-1 expression on T cells in solid tumors39 also suggests that T cell exhaustion can contribute to tumor outgrowth. Taken with studies exploring the mechanisms of checkpoint inhibition,40 41 and recent work showing that preventing T cell exhaustion promotes CAR T cell responses to solid tumors,42 43 the addition of costimulatory proteins or checkpoint blockade antibodies could therefore enhance BiTE efficacy.
This platform may also complement cellular immunotherapies, as indicated by recent work illustrating the impact of CAR T cells secreting BiTE protein in GBM.12 Although optimized therapeutic payloads delivered by GEMs may depend on indication, kinetics of immune response, and the type of companion cell therapy, it is appealing to consider this platform as an adjuvant to support the persistence, expansion, and functions of adoptively transferred cell therapies.
Although the current study tested GEMs in the context of cancer, GEMs could be beneficial in other disease settings, such as viral infections and autoimmunity, where manipulation of local immune responses may improve patient outcomes. The use of a repertoire of lentiviral vectors to create indication-specific GEMs encoding immune modulatory proteins may therefore provide targeted combination therapies for a wide range of human immune diseases.
The authors thank Joseph Cheng and James Matthaei for thoughtful discussion and advice in these studies; Adam Johnson for assistance with scFv design; and the Jensen Lab for the gift of cell lines and technical training for intracranial in vivo studies.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Contributors JLG designed and performed studies, analyzed and interpreted data, generated figures, and prepared manuscript. LRM and HC assisted with manuscript and figure edits. LRM, KD, HC, and BP performed experiments, analyzed data, and supported mouse studies. SAK designed BiTE construct. SB performed western blots. AD generated human PBMCs used in all studies. CAC advised on study design and manuscript preparation. All authors read and approved final manuscript.
Funding This work was supported by Steven Higgins Brain Tumor Fund, the Aldarra Foundation, and Stand Up to Cancer.
Competing interests The technology used to generate genetically engineered macrophages in this manuscript is covered under patent #US20170087185A1, Genetic engineering of macrophages for immunotherapy.
Patient consent for publication Not required.
Ethics approval Human blood products obtained commercially through Bloodworks Northwest. Mouse studies were conducted under Seattle Children’s Research Institute IACUC standards (Protocol # IACUC00088). Work with recombinant DNA was performed under IBC #1211.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data generated are included in this article and supplemental information.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.